Established in-house quantitative PCR (qPCR) assays to detect the Mycoplasma genitalium adhesion protein (MgPa) and the 16S rRNA gene were found to be comparable for screening purposes, with a kappa value of 0.97 (95% confidence interval [CI], 0.94 to 1.01) and no difference in bacterial load quantified (P ‫؍‬ 0.4399).
Limited knowledge exists regarding the epidemiology of Mycoplasma genitalium in the general population (3, 9, 12) . In the absence of adequate and reliable culture and approved commercial assay techniques, most laboratories use in-house nucleic acid amplification tests (NAATs) for detection of this bacterium. Quantitative PCR (qPCR) assays have been designed for a variety of M. genitalium targets (2, 5, 7, 8, 14, 15, 17, 18, 20, 22) , though the most cited qPCR assays are the one described by Jensen et al., which targets a 78-bp region of the M. genitalium adhesion protein (MgPa) and has a reported sensitivity of Ͻ5 copies per reaction (14) , and an assay by Yoshida et al. (22) , which targets a 517-bp region of the 16S rRNA gene with a sensitivity of Ͼ10 copies per reaction. Both of these targets are present as a single copy in the M. genitalium genome (10). Hardick et al. described a multiplex assay that incorporated both the MgPa and 16S rRNA gene qPCR assays (11) and found that the 16S rRNA target did not detect 59 of 607 samples (9.7%) in which MgPa was detected. Lack of detection by the 16S rRNA gene component could possibly be attributed to competition when the two targets were multiplexed, and the authors recommended further testing in singleplex reactions.
To investigate the issue of varying sensitivities between the MgPa and 16S rRNA gene assays, an initial experiment was carried out to determine the detection limit of each assay. A clinical sample equivalent to 1,200 copies/l of M. genitalium was diluted 1:4 to extinction and run in triplicate. Each assay consisted of 5 l template in a 20-l reaction on the LightCycler 480 real-time PCR system (Roche Diagnostics), using PCR conditions as described previously (8, 22 (21) , which consisted of specimens collected at the recruitment and at a 12-month follow-up. Sample processing and DNA extraction were as described previously (19) . Each sample was initially screened for the 16S rRNA gene target; then samples were stored at Ϫ30°C for a median of 25 months (average ϭ 22.2; range ϭ 1 to 29) before subsequent testing for the MgPa gene and retesting with the 16S RNA gene assay in cases where the assays gave discordant results. Nine DNA samples tested negative or yielded a low human ␤-globin gene signal, indicating inadequate sampling, and were removed from subsequent analyses.
Also removed from the study were three DNA samples from different patients in which M. genitalium was detected by the 16S rRNA assay (with 15, 68, and 129 copies per reaction; (4, 13) , and work in our own laboratory has shown levels of M. genitalium DNA to significantly reduce after three freeze-thaw cycles (data not shown). In future studies, freezing of samples destined for M. genitalium testing is not recommended, to avoid potential degradation. Of the 40 samples found to be positive by one or both methods (Table 1) , 38 (88.4%) were positive by both assays and 2 (4.7%) were positive by the MgPa assay only. Based on these results, the sensitivity and specificity of the 16S rRNA gene assay compared to those of the MgPa were 95.0% (95% confidence interval [CI], 0.831 to 0.994) and 100%, respectively (1) . Kappa analysis of these two methods gave a score of 0.973 (95% CI, 0.936 to 1.010), indicating an "almost perfect" agreement between these two assays (16) . The two discordant samples in this study with M. genitalium detected only by the MgPa assay were from the same patient but at different time periods (recruitment and at a 12-month follow up), with concentrations of 81 and 86 copies per reaction (Cq values ϭ 37.06 and 36.98, respectively).
Of the 38 samples that were positive for M. genitalium by both assays, only one sample showed evidence of slight degradation between retesting, showing a reduction from 411 copies per reaction initially with the 16S rRNA gene assay (Cq ϭ 33.16) to fewer than 10 copies per reaction when retested with both assays 26 months later (Cq ϭ 40.0 to 40.3). With the remaining 37 samples, the calculated concentrations for the MgPa assay ranged from 9 copies to 2.6 ϫ 10 5 copies per reaction (mean ϭ 3.0 ϫ 10 3 ; SD ϭ 5.5 ϫ 10 3 ), while results for the 16S rRNA assay ranged from 34 copies to 1.7 ϫ 10 5 copies per reaction (mean ϭ 2.5 ϫ 10 3 ; SD ϭ 4.1 ϫ 10 3 ). Using a paired t test, the concentrations given for each sample were not statistically different overall (P ϭ 0.44). This was confirmed by Deming regression analysis (6) giving a near-perfect line of best fit (Fig. 1) .
In summary, the MgPa and 16S rRNA gene assays appear equally suitable for the detection of M. genitalium in vaginal swabs. Further work is warranted to determine how effective these methods are for other clinical specimen types and to identify the reason(s) why two samples, from the same patient, gave rise to amplicons in the MgPa assay and not the 16S rRNA gene assay. These data will inform clinicians and researchers regarding the comparative performances of the two commonly used in-house assays for the detection of M. genitalium and are of particular relevance as routine testing and screening for the bacterium become increasingly common.
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